Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kazama, J. J.
Right arrow Articles by Gejyo, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kazama, J. J.
Right arrow Articles by Gejyo, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 31-35
© 2001 European Renal Association-European Dialysis and Transplant Association


Reduction of circulating ß2-microglobulin level for the treatment of dialysis-related amyloidosis

J. James Kazama, Hiroki Maruyama and Fumitake Gejyo

Department of Medicine (II), Niigata University Medical School, 1-757 Asahimachi-Dori, Niigata 951-8510, Japan

Abstract

Dialysis-related amyloidosis (DRA) is a common complication associated with long-term haemodialysis therapy. The elimination of ß2-microglobulin (ß2m), the major constituent of the amyloid fibrils in DRA, from circulation has been expected to bring some clinical benefit. Recently, a direct haemoperfusion method using selective ß2m absorption column to eliminate circulating ß2m has been introduced into clinical practice. According to a recently performed, prospective, multicentre study, joint pain, stiffness and daily activities were significantly improved in patients with established DRA after the introduction of selective ß2m absorption therapy. Meanwhile, although osteoarticular lesions progressed in the control group, there was no significant progression in the selective ß2m absorption therapy group. The absorptive affinity of the column for ß2m is not quite specific and therefore some other unknown uraemic toxins might be removed also. However, the improvement of joint pain and the ability to undertake daily activities showed reversed correlations against plasma ß2m clearance. Symptoms associated with the increased amount of extracorporeal circulation and increased economical burden are areas of concern for this therapy. In conclusion, selective ß2m absorption therapy was suggested to have the potential to ameliorate established DRA symptoms and simultaneously prevent its local development. The mechanism by which DRA symptoms are ameliorated remains obscure.

Notes

Correspondence and offprint requests to: J. James Kazama, Department of Medicine (II), Niigata University Medical School, 1-757 Asahimachi-Dori, Niigata 951-8510, Japan.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
D. H. Krieter, A. Morgenroth, A. Barasinski, H.-D. Lemke, O. Schuster, B. von Harten, and C. Wanner
Effects of a polyelectrolyte additive on the selective dialysis membrane permeability for low-molecular-weight proteins
Nephrol. Dial. Transplant., February 1, 2007; 22(2): 491 - 499.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.